肥大细胞增多症中PD-L1表达的变异性
本研究采用免疫组化和多重荧光染色系统分析肥大细胞增多症患者PD-1和PD-L1的表达。77%的系统性肥大细胞增多症(SM)病例肿瘤性肥大细胞(MC)膜表达PD-L1,92%(23/25)的皮肤肥大细胞增多症(CM)病例表达PD-L1,而健康/反应性骨髓及MDS、MPN等均无表达。PD-L1在样本间及样本内表达变异大(MC染色10%~100%,均值50%)。
要点
- 77%的系统性肥大细胞增多症病例肿瘤性肥大细胞膜表达PD-L1。
- 92%(23/25)的皮肤肥大细胞增多症病例表达PD-L1。
- PD-L1在肥大细胞上的染色比例变异大,范围为10%~100%(均值50%)。
核心结论
- 结果支持系统性肥大细胞增多症和皮肤肥大细胞增多症表达PD-L1,皮肤肥大细胞增多症表达PD-1。
- 数据支持在晚期肥大细胞增多症患者中探索抗PD-L1活性药物。
研究设计与样本
- 采用免疫组化和多重荧光染色,系统分析大量肥大细胞增多症患者中PD-1和PD-L1的表达。
主要发现
- 77%的系统性肥大细胞增多症病例显示肿瘤性肥大细胞PD-L1膜染色,包括3/3肥大细胞白血病、2/2侵袭性系统性肥大细胞增多症、1/2冒烟型系统性肥大细胞增多症、3/4惰性系统性肥大细胞增多症、9/12伴有相关血液肿瘤的系统性肥大细胞增多症(仅系统性肥大细胞增多症成分)。
- 92%(23/25)的皮肤肥大细胞增多症病例和1/2的骨髓肥大细胞白血病病例表达PD-L1。
- 15例健康/反应性骨髓、18例骨髓增生异常综合征、16例骨髓增殖性肿瘤、5例骨髓增生异常/骨髓增殖性肿瘤及3例单克隆肥大细胞激活综合征均未发现PD-L1表达。
- 样本间及样本内PD-L1表达可变,肥大细胞PD-L1染色范围为10%~100%(均值50%)。
- PD-1在4/27例皮肤肥大细胞增多症病例(15%)中弱染色,在系统性肥大细胞增多症或其他受检肿瘤中无表达;肥大细胞PD-1染色范围为20%~50%(均值27%)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Mastocytosis is a rare disease with heterogeneous clinical manifestations and few effective therapies. Programmed death-1 (PD-1) and its ligands (PD-L1 and PD-L2) protect tissues from immune-mediated damage and permit tumors to evade immune destruction. Therapeutic antibodies against PD-1 and PD-L1 are effective in the treatment of a variety of neoplasms. In the present study, we sought to systematically analyze expression of PD-1 and PD-L1 in a large number of patients with mastocytosis using immunohistochemistry and multiplex fluorescence staining. PD-L1 showed membrane staining of neoplastic mast cells (MCs) in 77% of systemic mastocytosis (SM) cases including 3 of 3 patients with MC leukemia, 2 of 2 with aggressive SM, 1 of 2 with smoldering SM, 3 of 4 with indolent SM, and 9 of 12 with SM with an associated hematologic neoplasm (SM component only). Ninety-two percent (23 of 25) of cutaneous mastocytosis (CM) cases and 1 of 2 with myelomastocytic leukemia expressed PD-L1, with no expression found in 15 healthy/reactive marrows, 18 myelodysplastic syndromes (MDSs), 16 myeloproliferative neoplasms (MPNs), 5 MDS/MPNs, and 3 monoclonal MC activation syndromes. Variable PD-L1 expression was observed between and within samples, with PD-L1 staining of MCs ranging from 10% to 100% (mean, 50%). PD-1 dimly stained 4 of 27 CM cases (15%), with no expression in SM or other neoplasms tested; PD-1 staining of MCs ranged from 20% to 50% (mean, 27%). These results provide support for the expression of PD-L1 in SM and CM, and PD-1 expression in CM. These data support the exploration of agents with anti-PD-L1 activity in patients with advanced mastocytosis.
引用
- Hatch EW, Geeze MB, Martin C, et al. Variability of PD-L1 expression in mastocytosis. Blood Adv. 2018. PMID: 29378725. doi:10.1182/bloodadvances.2017011551
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。